Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with Apatinib and Albumin Paclitaxel in Advanced Lung Adenocarcinoma
NCT04459078Phase 2Unknown
- Sponsor
- Hunan Cancer Hospital
- Start
- Aug 2020
- Primary completion
- May 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in lung adenocarcinoma, sponsored by Hunan Cancer Hospital. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT04459078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04459078.